Primary Amyloidosis Treatments
Find Primary Amyloidosis Treatments
Medications for Primary Amyloidosis
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Primary Amyloidosis.
Found 4 Approved Drugs for Primary Amyloidosis
Tafamidis
Brand Names
Vyndamax, Vyndaqel
Tafamidis
Brand Names
Vyndamax, Vyndaqel
Form: Capsule
Method of administration: Oral
FDA approval date: May 16, 2019
VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. VYNDAQEL and VYNDAMAX are transthyretin stabilizers indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. ( 1 )
Onpattro
Generic Name
Patisiran
Onpattro
Generic Name
Patisiran
Form: Injection
Method of administration: Intravenous
FDA approval date: August 13, 2018
Classification: Transthyretin-directed RNA Interaction
ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. ONPATTRO contains a transthyretin-directed small interfering RNA and is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Amvuttra
Generic Name
Vutrisiran
Amvuttra
Generic Name
Vutrisiran
Form: Injection
Method of administration: Subcutaneous
FDA approval date: June 13, 2022
Classification: Transthyretin-directed RNA Interaction
AMVUTTRA is a transthyretin-directed small interfering RNA indicated for the treatment of: the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Wainua
Generic Name
Eplontersen
Wainua
Generic Name
Eplontersen
Form: Injection
Method of administration: Subcutaneous
FDA approval date: December 21, 2023
Classification: Transthyretin-directed RNA Interaction
WAINUA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. WAINUA is a transthyretin-directed antisense oligonucleotide indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. ( 1 )
Showing 1-4 of 4
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances